Results for pancreatic cancer translation from English to Slovenian

pancreatic cancer
rak trebušne slinavke

patients with pancreatic cancer:
bolniki z rakom trebušne slinavke:

pancreatic
trebušni

for pancreatic cancer, it is 100 mg.
pri raku pljuč je priporočeni dnevni odmerek zdravila tarceva 150 mg, pri raku trebušne pa 100 mg.

pancreatic adenocarcinoma
adenokarcinom trebušne slinavke

pancreatic lipase.
pankreatična lipaza.

pancreatic cancer (tarceva administered concurrently with gemcitabine):
rak trebušne slinavke (zdravilo tarceva v kombinaciji z gemcitabinom):

infectious pancreatic necrosis
nalezljiva nekroza trebušne slinavke

pancreatic pseudocyst, subileus
pankreatična psevdocista, subileus

it has also been suggested that it may increase the risk of pancreatic cancer.
: "za bolezen glej hepatitis b.

pancreatic cancer (tarceva administered concurrently with gemcitabine in study pa.3):
rak trebušne slinavke (zdravilo tarceva v kombinaciji z gemcitabinom v študiji pa.3):

metastatic pancreatic cancer, in combination with gemcitabine (another anticancer medicine).
metastatskim rakom trebušne slinavke v kombinaciji z gemcitabinom (drugim zdravilom proti raku).

the usual dose is one tablet of tarceva 100 mg each day if you have metastatic pancreatic cancer.
običajni odmerek je ena tableta zdravila tarceva po 100 mg na dan, če imate metastatski rak trebušne slinavke.

tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
rak trebušne slinavke zdravilo tarceva je v kombinaciji z gemcitabinom indicirano za zdravljenje bolnikov z metastatskim rakom trebušne slinavke.

treatment of pancreatic cancer should be re-assessed after 4 to 8 weeks if no rash has developed.
v primeru, da se pri zdravljenju raka trebušne slinavke v prvih 4 do 8 tednih ne pojavijo kožni izpuščaji, je treba nadaljnje zdravljenje z zdravilom tarceva ponovno pretehtati.

the indication in pancreatic cancer is based on data from the pivotal phase 3 study jhay and the supporting study jhaz.
indikacija rak trebušne slinavke temelji na podatkih iz ključne študije iii. faze jhay in podporne študije jhaz.

onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas.
onivyde je zdravilo proti raku, ki se uporablja za zdravljenje oblike raka na trebušni slinavki, ki se imenuje metastatski adenokarcinom trebušne slinavke.

a second population pharmacokinetic analysis was conducted that incorporated erlotinib data from 204 pancreatic cancer patients who received erlotinib plus gemcitabine.
izvedli so še drugo populacijsko farmakokinetično analizo na osnovi podatkov o erlotinibu, pridobljenih pri 204 bolnikih z rakom trebušne slinavke, ki so prejemali erlotinib in gemcitabin.

routine screening is not recommended for bladder cancer, testicular cancer, ovarian cancer, pancreatic cancer, or prostate cancer.
domneval je, da so glavni vzrok za nastanek raka nepravilnosti v limfnem sistemu.

complications due to the underlying pancreatic cancer, especially biliary obstruction or presence of biliary stent, were identified as significant contributing factors.
zapleta zaradi osnovne bolezni, to je rak trebušne slinavke, ki so ju prepoznali kot pomembna dejavnika, ki prispevata k nastanku sepse, sta zlasti biliarna obstrukcija ali prisotnost biliarnega stenta.